CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on April 25, 2007
Clinical Journal of the American Society of Nephrology
© 2007 American Society of Nephrology
doi: 10.2215/CJN.03661106
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.03661106v1
2/4/750    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwarz, A.
Right arrow Articles by Haller, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwarz, A.
Right arrow Articles by Haller, H.
Related Collections
Right arrowRelated Article

Received November 2, 2006
Accepted on March 7, 2007

ORIGINAL ARTICLES

Renal Cell Carcinoma in Transplant Recipients with Acquired Cystic Kidney Disease

Anke Schwarz 1, Serap Vatandaslar , Saskia Merkel , and Hermann Haller

Department of Nephrology, Hannover Medical School, Hannover, Germany


1 To whom correspondence should be addressed. E-mail: schwarz.anke{at}mh-hannover.de.


   Abstract

Acquired cystic kidney disease (ACKD) is a widely known renal cell carcinoma risk factor. An ultrasound screening of the native kidneys in all renal transplant patients of a renal outpatient clinic who received a transplant between 1970 and 1998 and presented between 1997 and 2003 (n = 916) was initiated prospectively. A total of 561 patients were screened. A total of 129 (23%) patients had ACKD; 46 (8.2%) patients had complex renal cysts (Bosniak classification, category IIF to III); and eight (1.5%) patients had newly diagnosed renal cell carcinoma, seven of which were associated with ACKD (category IV). One patient had renal cell carcinoma in the transplanted kidney. Together with 19 patients of the cohort with formerly diagnosed renal cell carcinoma (18 of them associated with ACKD), the prevalence of renal cell carcinoma among all patients was 4.8%; among the patients with ACKD, it was 19.4% (without ACKD 0.5%; P = 0.0001); and among the patients with complex renal cysts (category IIF to III), it was 54.4%. The patients with ACKD were older (54 ± 13 versus 51 ± 14 yr; P = 0.048), more often male (65 versus 54%; P = 0.03), more often had heart disease (44 versus 29%; P = 0.001), had larger kidneys (6.9 and 6.8 cm versus 6.0 and 5.9 cm; P < 0.001), and had more calcifications (29 versus 15%; P = 0.002). Renal cell carcinoma was bilateral in 26% of cases. Tumor histology was clear cell carcinoma in 58% and papillary carcinoma in 42% of cases; one patient had both. Only one patient had a lung metastasis, and no patient died. It is concluded that renal cell carcinoma occurs often after renal transplantation and that especially patients with ACKD should routinely be screened. Because ACKD after renal transplantation seems to be less frequent (23%) than during dialysis treatment (30 to 90%), renal transplantation may inhibit renal cell carcinoma.


Related Article

Acquired Cystic Kidney Disease and Renal Cell Cancer after Transplantation: Time to Rethink Screening?
John D. Scandling
Clin. J. Am. Soc. Nephrol. 2007 2: 621-622. [Full Text] [PDF]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Society of Nephrology.